Disclosed herein are pharmaceutical dosage forms comprising (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol, croscarmellose sodium, silicon dioxide, microcrystalline cellulose, and magnesium stearate. Such compositions are useful as an inhibitor of sodium-glucose cotransporters (SGLT) 1 and 2 and are intended for the treatment of conditions such as diabetes and related metabolic disorders.